Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”) announced that it has entered into a drug discovery partnership agreement with Aitia, Inc. (Headquarters: Cambridge, Massachusetts, USA; CEO: Colin Hill; “Aitia”).

Under the terms of the agreement, Aitia will utilize its REFS™ technology to build Gemini Digital Twins (GDTs) of neurological diseases and identify new therapeutic targets and biomarkers. Ono will have an exclusive worldwide option right to research, develop, and commercialize drug candidates to the targets identified by Aitia.

“Ono has long been committed to creating innovative medicines for diseases with high unmet medical needs, including neurological diseases. Through this collaboration, we are delighted to leverage cutting-edge REFS™ technology to identify true therapeutic targets in neurological diseases, where disease mechanisms are complex and not yet fully understood. We believe this will accelerate the development of innovative medicines. We will continue to expand our R&D pipeline in the neurology field and strive to deliver new treatments to patients,” said Seishi Katsumata, Corporate Officer / Executive Vice President, Discovery & Research of Ono.

“We are honored to partner with Ono, a company with a strong track record in the neurology field. By utilizing our state-of-the-art causal AI-powered REFS™ technology, we are confident that we can build Gemini Digital Twins that uncover true disease mechanisms and therapeutic targets that could not be identified with conventional AI, thereby accelerating the development of new therapies,” said Colin Hill, CEO and co-founder of Aitia.